Enzalutamide (MDV-3100)

///Enzalutamide (MDV-3100)

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not respond to Xtandi or Zytiga and will live longer if treated with a taxane based chemotherapy (docetaxel) regimen. A study in JAMA Oncology, showed that evaluating for the presence of circulating tumor cells (CTCs) with AR-V7 could optimize treatment protocols. The study looked at 161 men with progressing metastatic castration-resistant [...]

Xtandi In Combination with Zytiga Is Not Better Than Either Drug Alone

Often I have heard people ask why if one drug is effective we shouldn’t simply take two or three at the same time? The answer is simple, because we don’t know if combining multiple drugs will make any difference to a man’s survival. The only way we can be sure is with good evidence. Good evidence requires, in the case of drugs, doing a clinical trial to see if a certain type of combination will be beneficial. In such a late-stage clinical trial designed to see if Xtandi in addition to Zytiga along with a steroid worked any better than [...]

Enzalutamide Prescribing Info Includes New Information

Enzalutamide (Xtandi) has a new, expanded FDA label. The new label conforms with the clinical trial (TERRAIN) results that Xtandi is a superior drug to Casodex (bicalutamide) for men with metastatic castration-resistant prostate cancer (CRPC). The updated product label shows enzalutamide reduces the risk of radiographic progression or death by 40% vs. bicalutamide. Median radiographic progression-free survival was 19.5 months with enzalutamide compared with 13.4 months with bicalutamide. Steven Benner, MD, senior vice president, therapeutic area head for oncology development, Astellas, said in a statement, "The addition of data from the TERRAIN trial continues to build the body of evidence [...]

By | October 26th, 2016|Advanced Prostate Cancer, Casodex, enzalutamide, Uncategorized, Xtandi|0 Comments

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]